Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

BACKGROUND: Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This phase IIa study was part of a phase I/IIa study (NCT03386955), aimed to evaluate the efficacy and safety of rezivertinib as the first-line treatment for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Zhou, Jianying, Zhao, Yanqiu, Zhu, Bo, Zhang, Liangming, Li, Xingya, Fang, Jian, Shi, Jianhua, Zhuang, Zhixiang, Yang, Sheng, Wang, Donglin, Yu, Huiqing, Zhang, Longzhen, Zheng, Rongsheng, Greco, Michael, Wang, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827694/
https://www.ncbi.nlm.nih.gov/pubmed/36617560
http://dx.doi.org/10.1186/s12916-022-02692-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827694/
https://www.ncbi.nlm.nih.gov/pubmed/36617560
http://dx.doi.org/10.1186/s12916-022-02692-8

Ejemplares similares